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Abstract
Background: Remitting seronegative symmetrical synovitis with pitting edema syndrome is characterized by
symmetrical synovitis with pitting edema in the dorsum of the hands or feet. Most cases of remitting seronegative
symmetrical synovitis with pitting edema syndrome are idiopathic, but some are secondary to malignancy, autoimmune
disease, or neurodegenerative disorders. Pleural and pericardial effusions are unusual complications in idiopathic
remitting seronegative symmetrical synovitis with pitting edema syndrome.
Case presentation: A 74-year-old Japanese woman presented to our hospital with arthralgia and pitting edema in her
feet. She had pain in multiple joints, peripheral edema, and a markedly elevated erythrocyte sedimentation rate.
Enhanced computed tomography and laboratory data showed no evidence of malignancy. These findings suggested
that she had idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome. She also developed
respiratory distress because of bilateral pleural and pericardial effusions. Laboratory data showed that serum vascular
endothelial growth factor and interleukin-6 were significantly elevated. After administration of steroids, her pleural and
pericardial effusions decreased and finally disappeared. Furthermore, vascular endothelial growth factor and interleukin-6
decreased when the pleural and pericardial effusions disappeared.
Conclusions: Here we report the case of a patient with idiopathic remitting seronegative symmetrical synovitis with
pitting edema syndrome associated with life-threatening complications, including bilateral pleural and pericardial
effusions during the course of the illness, which led to respiratory failure and atrial fibrillation. Elevated vascular
endothelial growth factor and interleukin-6 may be associated with the cause of pleural and pericardial effusions in
idiopathic remitting seronegative symmetrical synovitis with pitting edema syndrome.
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Background
Remitting seronegative symmetrical synovitis with pitting
edema (RS3PE) syndrome is characterized by symmetrical
synovitis with pitting edema in the dorsum of the hands
or feet, predominantly involving the hands [1–3]. These
symptoms show a good response to low-dose corticoste-
roids, and remission can be maintained [1–3]. RS3PE
syndrome shows a benign clinical course because of the
good response to steroid treatment. However, patients
with RS3PE syndrome rarely develop pleuritis, which
induces pleural effusion [4–8]. Here we report the case of
a patient with RS3PE syndrome associated with life-
threatening complications including bilateral pleural and
pericardial effusions during the course of the illness,
which led to respiratory failure and atrial fibrillation.
Case presentation
A 74-year-old Japanese woman gradually developed gen-
eral malaise and loss of appetite. In addition, arthralgia
and pitting edema in her feet appeared. Her laboratory
findings revealed an elevated white blood cell (WBC)
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count and C-reactive protein (CRP). She was admitted
to our hospital for further examination. She had an op-
eration for endometrial cancer at the age of 72 and had
no family history.
On admission, her blood pressure was 129/76 mmHg,
heart rate was 101/minute, respiratory rate was 18/mi-
nute, and body temperature was 39.1 °C. A physical
examination revealed pitting edema on the dorsum of
her hands and feet. Her neurological examination was
unremarkable. However, she had difficulty with squatting
and walking because of arthralgia in her proximal lower
limbs. Laboratory testing showed a WBC of 11700/μL,
CRP of 6.7 mg/dL, erythrocyte sedimentation rate of 44
mm/hour, total protein of 5.8 g/dL, and albumin of 2.3
g/dL. Rheumatoid factor, anti Ro/SSA antibody, anti
La/SSB antibody, anti Scleroderma 70 antibody, and anti
cyclic citrullinated peptide antibody were negative.
Serum interleukin-6 (IL-6) and vascular endothelial
growth factor (VEGF) were markedly increased to 285 pg/
mL (normal; <2 pg/mL) and 1820 pg/mL (normal; 262
±228 pg/mL) [9], respectively. Her human leukocyte anti-
gen (HLA) typing included B7. A chest X-ray revealed
mild pleural effusion on the right side. Electrocardiog-
raphy showed a complete right bundle branch block with-
out ST-T change. Echocardiography revealed a slight
pericardial effusion surrounding her entire heart.
She had a high fever, general malaise, and muscle
weakness, and her laboratory tests revealed elevated in-
flammatory markers including WBC, CRP, and erythro-
cyte sedimentation rate. Because infectious disease was
suspected, tazobactam-piperacillin 13.5 mg/day was
started. On day 2, atrial fibrillation appeared on the
electrocardiography monitor. A chest X-ray showed
that the pleural effusion had increased in both lungs.
Furthermore, echocardiography demonstrated increased
pericardial effusion around her heart. On day 3, she devel-
oped respiratory failure, and oxygen administration was
started by nasal cannula at a dose of 3 L/minute.
Enhanced chest-abdominal computed tomography (CT)
showed marked bilateral pleural and pericardial effusions
without neoplastic lesions (Fig. 1a). Analysis of the pleural
effusion revealed exudate with an increased protein level
and neutrophils, but cytological evaluation of the pleural
effusion revealed no evidence of malignancy. Cultures of
blood and pleural effusion were all negative. Our patient
fulfilled the diagnostic criteria of RS3PE syndrome includ-
ing: 1) pitting edema of the hands and feet; 2) sudden on-
set of polyarthritis; 3) onset at age 50 years or older; and
4) negative serology for rheumatoid factors [1]. From day
6, she was treated with methylprednisolone administered
intravenously at a dose of 1000 mg/day for 3 days. After
steroid therapy, her fever rapidly improved, and blood
tests revealed a decrease in CRP to 1.71 mg/dL. The
pleural and pericardial effusions on chest CT decreased
(Fig. 1b). When the pericardial effusion decreased, her
atrial fibrillation disappeared. After steroid pulse therapy,
oral prednisolone administration at a dose of 15 mg/day
was started. Her respiratory failure immediately improved,
and then she no longer required oxygen administration. A
chest CT performed on day 38 revealed that the pleural
and pericardial effusions had disappeared (Fig. 1c). On day
45, she was discharged. One year later, the prednisolone
dosage was decreased to 8 mg/day, but the patient experi-
enced no recurrence of symptoms. At the 1-year examin-
ation, no malignancy was found. Serum IL-6 and VEGF
were significantly decreased to 1.3 pg/mL and 562 pg/mL,
respectively.
Discussion
RS3PE syndrome was first reported in 1985 by McCarty
et al. and is characterized by: 1) good prognosis (Remit-
ting); 2) negativity for antibodies, including rheumatoid
factors (Seronegative); 3) symmetry (Symmetrical); and
4) synovitis with pitting edema of the dorsum of the
Fig. 1 Chest computed tomography. a Chest computed tomography on the day before steroid therapy showed moderate bilateral pleural (arrows)
and pericardial effusions (arrowhead). b Chest computed tomography after steroid therapy showed that the pleural effusion had decreased (arrows)
and the pericardial effusion had disappeared. c Follow-up chest computed tomography on day 38 showed no pleural or pericardial effusions
Yanamoto et al. Journal of Medical Case Reports  (2016) 10:198 Page 2 of 4
hands and feet (Synovitis with Pitting Edema) [1]. Other
common characteristics of RS3PE syndrome include acute
onset in older persons, absence of bone erosion, inflam-
matory findings on blood examination, and painless limi-
tation of movement of the wrist and fingers [2, 3]. Most
cases of RS3PE syndrome are idiopathic, although the syn-
drome has been associated with malignancy, polymyalgia
rheumatica, Parkinson’s disease, Sjögren’s syndrome, and
ankylosing spondylitis [2, 3]. Our patient had acute onset
of bilateral shoulder pain and edema on the dorsum of
both feet at the age of 74. These symptoms were resolved
by treatment with steroids, indicating the diagnosis of
RS3PE syndrome. Because her enhanced CT and la-
boratory data showed no disease that may have induced
RS3PE syndrome, she was diagnosed with idiopathic
RS3PE syndrome.
Previously, five case reports of pleural effusion in pa-
tients with RS3PE syndrome have been reported (Table 1).
Four cases showed the presence of pleural effusion in idio-
pathic RS3PE syndrome [4–7]. In these cases, the pleural
effusion responded well to steroid therapy [4–7]. Taken
together with our patient, pleuritis may occur rarely in
patients with RS3PE syndrome. One case with RS3PE
syndrome had both pleural and pericardial effusions [8].
However, this case of RS3PE syndrome was secondary to
angioimmunoblastic T-cell lymphoma [8], which may in-
duce pleural and pericardial effusions. Our case showed
that pericarditis-induced pericardial effusion occurred in
the patients with idiopathic RS3PE syndrome.
Several reports suggested that serum IL-6 and VEGF
are increased in RS3PE syndrome [2, 10–12], suggesting
that these cytokines may be associated with symptoms
of RS3PE syndrome. In our patient, serum IL-6 and
VEGF were also markedly elevated when pleural and
pericardial effusions were increased. After steroid ther-
apy, levels of serum IL-6 and VEGF decreased when
pleural and pericardial effusions disappeared. IL-6 is an
important cytokine that induces VEGF production [13].
VEGF induces vascular endothelial cell proliferation, en-
hances angiogenesis, and accelerates vascular permeabil-
ity [13]. Elevated VEGF and IL-6 may be associated with
the cause of pleural and pericardial effusions in idio-
pathic RS3PE syndrome.
In general, idiopathic RS3PE syndrome is considered
to be a benign disorder; however, patients with RS3PE
syndrome may develop life-threatening respiratory and
circulatory problems due to pleuritis and endocarditis.
Therefore, physicians should be aware of these compli-
cations when diagnosing RS3PE syndrome and deter-
mining treatment.
Conclusions
Our findings suggest that pleuritis and endocarditis are
rare complications in idiopathic RS3PE syndrome. These
complications may be associated with increased serum
VEGF and IL-6.
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